Catalent to Commercially Supply Palatin FSD Pen Injectors
PTSM: Pharmaceutical Technology Sourcing and Management
The pen injectors will be produced at Catalent’s Brussels, Belgium facility.
Catalent Pharma Solutions and Palatin Technologies have reached a commercial supply agreement to support the launch of Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD), Catalent said in a June 30, 2016 press announcement. Bremelanotide is a subcutaneous injectable peptide melanocortin receptor agonist and is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. The bremelanotide pen injectors will be produced at Catalent's 265,000-sq.-ft. Brussels, Belgium facility, Catalent noted. Phase III trials of bremelanotide are currently ongoing, with launch anticipated in 2018.
Source: Catalent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
